Ly3090106 - sq (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01925157 (ClinicalTrials.gov) | August 2013 | 15/8/2013 | A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA) | A Single-Dose, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3090106 in Healthy Subjects and Subjects With Rheumatoid Arthritis | Rheumatoid Arthritis | Biological: LY3090106 - SQ;Biological: LY3090106 - IV;Biological: Placebo - SQ | Eli Lilly and Company | NULL | Completed | 18 Years | 80 Years | Both | 43 | Phase 1 | Bulgaria;Moldova, Republic of;Poland;Romania;Hungary;United States |